Updates on the Diagnosis and Management of Alzheimer's Disease
Screening, Imaging, and Emerging Treatment Strategies
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Albert MS, et al. Alzheimers Dement. 2011;7:270-279.
Therapeutic application of melatonin in mild cognitive impairment
Cardinali DP, et al. Am J Neurodegener Dis. 2012;1:280-291.
Alzheimer’s disease: strategies for disease modification
Citron M. Nat Rev Drug Discov. 2010;9:387-398.
International Work Group Criteria for the Diagnosis of Alzheimer Disease
Cummings JL, et al. Med Clin N Am. 2013;97:363-368.
Amyloid-beta assessed by florbetapir F-18 PET and 18-month cognitive decline: A multicenter study
Doraiswamy PM, et al. Neurology. 2012;79:1636-1644.
Cerebrospinal Fluid tau/Beta Amyloid 42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Fagan AM, et al. Arch Neurol. 2007;64:343-349.
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup
McKhann GM, et al. Alzheimers Dement. 2011;7:263-269.
Practical Guidelines for the Recognition and Diagnosis of Dementia
Galvin JE, Sadowsky CH. J Am Board Fam Med. 2012;25:367-382.
Multi-modal techniques for diagnosis and prognosis of Alzheimer’s disease
Perrin RJ, et al. Nature. 2009;461:916-922.
Snapshot:pathology of Alzheimer’s disease
Selkoe DJ. Cell. 2013;154:468-468.e1.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup
Sperling RA, et al. Alzheimers Dement. 2011;7:280-292.
Comparison of International Working Group criteria and National Institute on Aging-Alzheimer’s Association criteria for Alzheimer’s disease
Visser PJ, et al. Alzheimers Dement. 2012;8:560-563.
Patient Resources
Effective Communication in Alzheimer's Disease
Finding Information and Support
Tools
Montreal Cognitive Assessment
This is a 10-minute cognitive screening tool designed to assist physicians in the detection of mild cognitive impairment. A screening score less than 26 yields a positive screen for mild cognitive impairment. It has very good sensitivity and specificity.
Nasreddine ZS, et al. J Am Geriatr Soc. 2005;53:695-699.
Alzheimer’s Disease Assessment Scale-Cognition (ADAS-Cog)
The ADAS-Cog is designed to measure the severity of cognitive impairment symptoms during the assessment of Alzheimer’s disease. It is recommended for second stage or a more detailed evaluation.
Rosen WG, et al.Am J Psychiatry. 1984;141:1356-1364.
Modified Mini Mental Exam (3MS)
The mini mental exam is a brief test of cognitive function and current mental state. It is commonly used as a screening tool to test for dementia. The modified mini mental exam version is designed to sample a broader variety of cognitive functions and enhance the reliability and validity of the scores.
Teng EL, Che HC. J Clin Psychiatry. 1987;48:314-318.
Guidelines
International Work Group (IWG) Criteria for the Diagnosis of Alzheimer Disease
The IWG guidelines allow for the highly specific diagnosis of Alzheimer’s disease (AD). They identify a unified spectrum of 3 stages, from at-risk state asymptomatic to symptomatic prodromal AD and AD dementia. Biomarker confirmation is required for the diagnosis of AD at any clinical stage.
Cummings JL, et al. Med Clin N Am. 2013;97:363-368.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association (NIA-AA) workgroups on diagnostic guidelines for Alzheimer’s disease
The NIA-AA working group put forth criteria for the diagnosis of symptomatic mild cognitive impairment. The core clinical criteria is intended for use by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis.
Albert MS, et al. Alzheimers Dement. 2011;7:270-279.
Updates on the Diagnosis and Management of Alzheimer’s Disease
Screening, Imaging, and Emerging Treatment Strategies
| Faculty: | Adam S. Fleisher, MD, MAS; Lon S. Schneider, MD, MS; Dennis J. Selkoe, MD; and Eric G. Tangalos, MD, FACP, AGSF, CMD |
| Release: | 03/07/2014 |
| Expiration: | 03/07/2015 |
